Ocata Shareholders Hold Out On Astellas Offer
This article was originally published in PharmAsia News
Executive Summary
Another tender offer deadline has come and gone for Astellas in its pursuit of Boston's Ocata Therapeutics, but the Japanese firm remains committed to pursuing its quarry.